AN2 Therapeutics
ANTX
37 hedge funds and large institutions have $8.78M invested in AN2 Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 9 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
3% less funds holding
Funds holding: 38 → 37 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
20.19% less ownership
Funds ownership: 47.65% → 27.46% (-20%)
55% less capital invested
Capital invested by funds: $19.5M → $8.78M (-$10.7M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$649K |
| 2 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$590K |
| 3 |
Morgan Stanley
New York
|
+$212K |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
+$137K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$7.82M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.36M |
| 3 |
AC
Aldebaran Capital
Carmel,
Indiana
|
-$553K |
| 4 |
Two Sigma Advisers
New York
|
-$209K |
| 5 |
Two Sigma Investments
New York
|
-$126K |
ANTX Hedge Fund Activity: Q2 2025 in Review
37 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q2 2025, worth a combined $8.78M — down 55% from $19.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ANTX and 8 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 9 added.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $649K. The largest seller was BML Capital Management, exiting entirely with an estimated $7.82M sold.
- 37 institutional investors held AN2 Therapeutics (ANTX) as of Q2 2025, down from 38 in Q1 2025.
- Funds reported $8.78M of AN2 Therapeutics stock for Q2 2025, down 55% quarter-over-quarter.
- 8 funds opened new AN2 Therapeutics positions in Q2 2025 and 9 closed out, a net change of -1 holder.
- The largest AN2 Therapeutics buyer in Q2 2025 was Stonepine Capital Management, an estimated $649K added.
- The largest AN2 Therapeutics seller in Q2 2025 was BML Capital Management, an estimated $7.82M sold.
Based on aggregated 13F filings for Q2 2025.